Healthcare Equipment and Supplies
Company Overview of One Lambda, Inc.
One Lambda, Inc. develops and distributes various lines of human leukocyte antigen (HLA) typing and antibody detection tests. It provides transplant monitoring solutions for antibody detection; serological typing products, including tissue typing trays, monoclonal trays, reagents, and ancillary products; and a comprehensive line of molecular products that supports laboratories and physicians with reverse sequence specific oligonucleotide, sequence specific primer, and sequence-based typing products for HLA Class I and II typing. The company also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. ...
21001 Kittridge Street
Canoga Park, CA 91303-2801
Founded in 1984
Key Executives for One Lambda, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Chairman of the Board
Vice President of Operations
Vice Chair of the Board and Secretary
Compensation as of Fiscal Year 2015.
One Lambda, Inc. Key Developments
One Lambda, Inc. Announces Availability of Test for Detecting HNA-3
Apr 14 15
One Lambda, Inc. announced the availability of the only FDA cleared and CE marked LABScreen Multi assay for detecting HNA-3, as well as HLA. What's more, the new LABScreen Multi screening kit is capable of processing up to 96 samples in under four hours. Both anti-HLA and anti-HNA antibodies have been implicated in the clinical cases of transfusion-related acute lung injury (TRALI). The new LABScreen Multi antibody screening kit simultaneously detects HLA Class I, HLA Class II and HNA 1a, 1b, 1c, 2, 3a, 3b, 4a, 5a and 5b antibodies using the high-throughput Luminex platform. TRALI is a serious complication from blood transfusions that can cause pulmonary edema and is the cause of transfusion-related death. Several studies have implicated that TRALI may result from leukocyte and neutrophil antibodies in the transfused blood. This new product screens potential donors for antibodies to both HLA and HNA antigens at the same time. The LABScreen Multi assay is used to screen up to 96 donors for HLA and HNA all in one run. It's easy to use, to interpret and, with the HLA Fusion software, data for both antigen groups is easy to analyze. Compared to conventional testing methods for neutrophil antibodies, the LABScreen Multi assay offers an easy, efficient method for antibody screening. Launched at American Association of Blood Banks in Philadelphia. This bead-based assay is capable of processing up to 96 donors on a single plate in under 4 hours and multi plates can be processed simultaneously making it ideal for clinical labs processing large amount of samples.
DIAXONHIT's InGen Announces Renewal of Commercial Partnership with One Lambda, Inc. for Diagnostic Tests in Transplantation
Nov 12 14
DIAXONHIT announced on behalf of its affiliate, InGen, the renewal of the exclusive commercial partnership for the commercialization in France of diagnostic tests for transplantation developed by One Lambda, Inc. The renewal of this exclusive partnership demonstrates the quality of sales team and the confidence of One Lambda in marketing abilities. It enables the Group to strengthen its investment strategy over the long term in all areas of transplantation in order to further develop this critical market. One Lambda develops and distributes several lines of HLA typing tests utilizing both serological and molecular technologies. It manufactures a comprehensive line of antibody detection products that have been designed to monitor transplant patients, both pre- and post-transplant. They are used to detect HLA antibodies that may cause graft rejection. One Lambda also manufactures laboratory instrumentation, and computer software that are used to simplify and automate testing procedures and final test evaluations. With five different product lines, One Lambda allows laboratories to choose a solution that best suits their needs. HLA tests marketed by DIAXONHIT's InGen are used to assess the compatibility between donor and recipient before transplantation, and to follow-up transplanted patients in order to monitor potential rejection and adjust immunosuppressive treatments accordingly. Before transplantation, HLA typing is performed routinely by serology or molecular biology, as well as detection of anti-HLA antibodies synonymous with increased risk of rejection. After transplantation, rejection is monitored with tests that identify anti-HLA antibodies present in patients. All these tests are performed in the HLA laboratories of the French Blood Bank, and in histocompatibility (immunology) laboratories of university hospitals. The field of transplantation covers all activities related to organ and bone marrow transplants. In 2013, 5,123 transplants were performed in France, up 45% since 2000() with rejection remaining the main risk. The rates of acute rejection within a year after transplantation ranging from 5% (kidney) to 50% (lung)(2), the need for reliable diagnostic tests is essential.
One Lambda, Inc. Announces Licensing Agreement with GenoDive Pharma, Inc
Jun 6 14
One Lambda Inc. has entered into a licensing agreement with GenoDive Pharma Inc. for exclusive rights to GenoDive's long-range primers and
amplification conditions for human leukocyte antigen (HLA) locus-specific amplification. The agreement covers GenoDive's primers and conditions for HLA A, B, C, DRB1, DRB345, DQA1, DQB1, DPA1 and DPB1 loci.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|